![]() ![]() MRC = Medical Research Council breathlessness / dyspnoea scale CAT = COPD Assessment Test.SABA = Short-acting beta 2 agonist SAMA = Short-acting muscarinic antagonist LABA = Long-acting beta 2 agonist LAMA = Long-acting muscarinic antagonist ICS = Inhaled corticosteroid.DPI = Dry powder inhaler SMI = Soft mist inhaler pMDI = Pressurised metered dose inhaler BAI = Breath actuated inhaler.Local and national resources which support patient training can be accessed via links at the bottom of the page. When discussing inhaled treatment options, consideration should also be given to the environmental impact of inhalers. Adherence to treatment regimens should also be checked. It is essential that patients can demonstrate the proper inhaler technique when prescribing an inhaler device recheck patient technique at each visit to ensure continued correct use of the inhaler. Patient preference should be considered when prescribing treatments. ![]() Treatment regimens should be patient-specific, and individualised. Therapy should be reviewed annually and following an exacerbation. Non inhaled prevention and maintenance strategies are essential in the management of COPD (see slider below) It is important to establish that patients meet the diagnostic criteria for COPD before commencing treatment. Diagnosis is not covered in the guidance below. The information is supported by local respiratory specialists and is intended to guide and rationalise treatment choices when managing patients with COPD. Where recommendations have been made by NICE (2019) this is indicated in the text. The following recommendations are largely based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD) 2019 Report. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |